November 8, 2022 • Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments

November 2, 2022 • New patent application associating NFL-101 with other smoking cessation treatments

October 25, 2022 • 2022 first-half business and earnings

October 5, 2022 • NFL Biosciences partners with Themis Medicare for the development of NFL-101 in India

June 24, 2022 • NFL Biosciences to present at the H.C.Wainwright 1st annual mental health conference

May 25, 2022 • NFL Biosciences, committed to fight against smoking, fully supports World No Tobacco Day on May 31

May 11, 2022 • Decision to approve the issuing of its patent in South Korea

April 11, 2022 • Notice of allowance of its patent in China

March 28, 2022 • 2021 full-year business and earnings update

February 2, 2022 • Co-development agreement for a drug candidate to reduce alcohol consumption

December 14, 2021 • Phase II/III clinical trial launched for smoking cessation

November 17, 2021 • Agreement signed with Diverchim to manufacture its active ingredients

October 4, 2021 • 2021 half-year financial and business report

September 21, 2021 • Approval for its patent to be granted in the United States

September 15, 2021 • Phase II/III clinical trial for NFL-101 for smoking cessation approved in France

September 6, 2021 • Analyst coverage launched with Invest Securities

July 20, 2021 - Establishment of a liquidity agreement (in French only)

June 30, 2021 • Success of the IPO on Euronext Growth Paris

June 16, 2021 • NFL Biosciences launches its initial public offering on Euronext Growth Paris (in French only)

June 2, 2021 • French smoking cessation innovation approved for Phase II clinical trial (in French only)